FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2915663366> ?p ?o ?g. }

• W2915663366 endingPage "642" @default.
• W2915663366 startingPage "635" @default.
• W2915663366 abstract "Ipilimumab is an anti-CTLA4 monoclonal antibody with demonstrated efficacy for metastatic melanoma in randomized controlled trials, including in the first-line setting. Population-based outcomes directly compared with historic chemotherapy treatment in metastatic or unresectable melanoma are lacking. Using population-based data from the province of Ontario, the benefit of first-line ipilimumab was estimated by comparing outcomes of patients treated with first-line dacarbazine over the period 2007–2009 with patients treated over the period 2010–2015 with first-line ipilimumab. Cutaneous and noncutaneous cases were included. The administrative data set utilized was high-dimensional; meaning, there was a large number of variables relative to the sample size. To adjust for important confounders among the many available variables, we utilized a double-selection method, a modified machine learning algorithm to extract the important variables that were related to both survival times and treatment usage. Time-dependent treatment modeling was utilized. Among the 2793 melanoma patients receiving palliative treatment (systemic therapy, surgery, or radiation) in Ontario (2007–2015), there were 289 patients treated with first-line ipilimumab (2010–2015) and 175 patients treated with first-line dacarbazine (2007–2009). For first-line ipilimumab, the adjusted hazard ratio compared with dacarbazine for overall survival (OS) was 0.63 (95% confidence interval: 0.47–0.84) with a 1-year survival of 46.5 versus 18.9% with dacarbazine. In subgroup analysis, ipilimumab was associated with improved OS across groups (age, sex, comorbidity, income quintile, previous interferon). First-line ipilimumab was found to have a significant OS benefit compared with historical controls in a population including those patients not routinely included in clinical trials. The treatment effect was similar to randomized controlled trials, suggesting a meaningful benefit when utilized in a population-based setting." @default.
• W2915663366 created "2019-03-02" @default.
• W2915663366 creator A5009914868 @default.
• W2915663366 creator A5047907079 @default.
• W2915663366 creator A5073771690 @default.
• W2915663366 creator A5077856644 @default.
• W2915663366 creator A5086588458 @default.
• W2915663366 date "2019-12-01" @default.
• W2915663366 modified "2023-10-16" @default.
• W2915663366 title "A population-based study of the treatment effect of first-line ipilimumab for metastatic or unresectable melanoma" @default.
• W2915663366 cites W1934545069 @default.
• W2915663366 cites W2027230955 @default.
• W2915663366 cites W2029822285 @default.
• W2915663366 cites W2057780602 @default.
• W2915663366 cites W2066671159 @default.
• W2915663366 cites W2097995306 @default.
• W2915663366 cites W2123363005 @default.
• W2915663366 cites W2133075384 @default.
• W2915663366 cites W2164281389 @default.
• W2915663366 cites W2308122693 @default.
• W2915663366 cites W2560367415 @default.
• W2915663366 cites W2588698239 @default.
• W2915663366 cites W2763078237 @default.
• W2915663366 cites W2804772768 @default.
• W2915663366 cites W2811030359 @default.
• W2915663366 doi "https://doi.org/10.1097/cmr.0000000000000582" @default.
• W2915663366 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6887627" @default.
• W2915663366 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30789386" @default.
• W2915663366 hasPublicationYear "2019" @default.
• W2915663366 type Work @default.
• W2915663366 sameAs 2915663366 @default.
• W2915663366 citedByCount "4" @default.
• W2915663366 countsByYear W29156633662020 @default.
• W2915663366 countsByYear W29156633662021 @default.
• W2915663366 countsByYear W29156633662022 @default.
• W2915663366 crossrefType "journal-article" @default.
• W2915663366 hasAuthorship W2915663366A5009914868 @default.
• W2915663366 hasAuthorship W2915663366A5047907079 @default.
• W2915663366 hasAuthorship W2915663366A5073771690 @default.
• W2915663366 hasAuthorship W2915663366A5077856644 @default.
• W2915663366 hasAuthorship W2915663366A5086588458 @default.
• W2915663366 hasBestOaLocation W29156633662 @default.
• W2915663366 hasConcept C121608353 @default.
• W2915663366 hasConcept C126322002 @default.
• W2915663366 hasConcept C143998085 @default.
• W2915663366 hasConcept C207103383 @default.
• W2915663366 hasConcept C2776694085 @default.
• W2915663366 hasConcept C2777658100 @default.
• W2915663366 hasConcept C2777701055 @default.
• W2915663366 hasConcept C2780964509 @default.
• W2915663366 hasConcept C2781433595 @default.
• W2915663366 hasConcept C2908647359 @default.
• W2915663366 hasConcept C44249647 @default.
• W2915663366 hasConcept C502942594 @default.
• W2915663366 hasConcept C71924100 @default.
• W2915663366 hasConcept C99454951 @default.
• W2915663366 hasConceptScore W2915663366C121608353 @default.
• W2915663366 hasConceptScore W2915663366C126322002 @default.
• W2915663366 hasConceptScore W2915663366C143998085 @default.
• W2915663366 hasConceptScore W2915663366C207103383 @default.
• W2915663366 hasConceptScore W2915663366C2776694085 @default.
• W2915663366 hasConceptScore W2915663366C2777658100 @default.
• W2915663366 hasConceptScore W2915663366C2777701055 @default.
• W2915663366 hasConceptScore W2915663366C2780964509 @default.
• W2915663366 hasConceptScore W2915663366C2781433595 @default.
• W2915663366 hasConceptScore W2915663366C2908647359 @default.
• W2915663366 hasConceptScore W2915663366C44249647 @default.
• W2915663366 hasConceptScore W2915663366C502942594 @default.
• W2915663366 hasConceptScore W2915663366C71924100 @default.
• W2915663366 hasConceptScore W2915663366C99454951 @default.
• W2915663366 hasIssue "6" @default.
• W2915663366 hasLocation W29156633661 @default.
• W2915663366 hasLocation W29156633662 @default.
• W2915663366 hasLocation W29156633663 @default.
• W2915663366 hasLocation W29156633664 @default.
• W2915663366 hasOpenAccess W2915663366 @default.
• W2915663366 hasPrimaryLocation W29156633661 @default.
• W2915663366 hasRelatedWork W2008642727 @default.
• W2915663366 hasRelatedWork W2048091645 @default.
• W2915663366 hasRelatedWork W2088165794 @default.
• W2915663366 hasRelatedWork W2123363005 @default.
• W2915663366 hasRelatedWork W2124966844 @default.
• W2915663366 hasRelatedWork W2171124087 @default.
• W2915663366 hasRelatedWork W2513285370 @default.
• W2915663366 hasRelatedWork W2773756552 @default.
• W2915663366 hasRelatedWork W3086309329 @default.
• W2915663366 hasRelatedWork W4312123989 @default.
• W2915663366 hasVolume "29" @default.
• W2915663366 isParatext "false" @default.
• W2915663366 isRetracted "false" @default.
• W2915663366 magId "2915663366" @default.
• W2915663366 workType "article" @default.